Circulation Heart Failure · 2014 · 49 citations · 20 references
MedicineCardiologyPhysiologyIron Metabolism DisordersRenal PathologyRenal PathophysiologyAnemiaCardiac BiomarkersCardiovascular DiseaseChronic Kidney DiseaseHeart FailureRenal DiseaseAnemia PathogenesisAnemia-related Cardiovascular RiskBiomarkers Of Organ DysfunctionCardiac RemodelingHeart Failure Molecular MechanismsLeft Ventricular Systolic FunctionSystemic Inflammation MarkersSystolic Dysfunction
BACKGROUND: Anemia is a highly prevalent and strong independent prognostic marker in heart failure (HF), yet this association is not completely understood. Whether anemia is simply a marker of disease severity and concomitant chronic kidney disease or represents the activation of other detrimental pathways remains uncertain. We sought to determine which pathophysiological pathways are exacerbated in patients with HF, reduced ejection fraction (HFrEF) and anemia in comparison with those without anemia. METHODS AND RESULTS: In a prospective study involving 151 patients, selected biomarkers were analyzed, each representing proposed contributive mechanisms in the pathophysiology of anemia in HF. We compared clinical, echocardiographic, and circulating biomarkers profiles among patients with HFrEF and anemia (group 1), HFrEF without anemia (group 2), and chronic kidney disease with preserved EF, without established HF (chronic kidney disease control group 3). We demonstrate here that many processes other than those related to chronic kidney disease are involved in the anemia-HF relationship. These are linked to the pathophysiological mechanisms pertaining to left ventricular systolic dysfunction and remodeling, systemic inflammation and volume overload. We found that levels of interleukin-6 and interleukin-10, specific markers of cardiac remodeling (procollagen type III N-terminal peptide, matrix metalloproteinase-2, tissue inhibitor of matrix metalloproteinase 1, left atrial volume), myocardial stretch (NT-proBNP [N-terminal probrain natriuretic peptide]), and myocyte death (troponin T) are related to anemia in HFrEF. CONCLUSIONS: Anemia is strongly associated not only with markers of more advanced and active heart disease but also with the level of renal dysfunction in HFrEF. Increased myocardial remodeling, inflammation, and volume overload are the hallmarks of patients with anemia and HF. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00834691.
20
Hemodilution Is Common in Patients With Advanced Heart Failure
Ana-Silvia Androne, Stuart D. Katz, Lars Lund et al. · Circulation · 2003 · 483 citations · Full text
Medicine, Cardiology, Hematology +14
Quantification of F2-isoprostanes as a biomarker of oxidative stress
Ginger L. Milne, Stephanie Sanchez, Erik S. Musiek et al. · Nature Protocols · 2007 · 336 citations
Jean‐Claude Tardif, Eileen O’Meara, Michel Komajda et al. · European Heart Journal · 2011 · 301 citations · Full text
Iron status in patients with chronic heart failure
Ewa A. Jankowska, Hossein Ardehali, E. Koc-Zorawska et al. · European Heart Journal · 2012 · 277 citations · Full text
Medicine, Cardiology, Physiology +11